News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Policy
UK’s NICE Turns Down GlaxoSmithKline’s Tyverb Offer
October 14, 2008
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
LONDON, Oct 14 (Reuters) - Britain's healthcare cost effectiveness watchdog NICE has rebuffed GlaxoSmithKline's latest bid to get its drug Tyverb - for women with advanced breast cancer - into the state health system, the company said on Tuesday.
Twitter
LinkedIn
Facebook
Email
Print
Regulatory
Europe
GSK
MORE ON THIS TOPIC
FDA
New FDA draft guidance doubles down on expediting approvals of personalized gene therapies
October 28, 2026
·
4 min read
·
Heather McKenzie
Business
US biotechs take lion’s share of $54.5B VC money raised since 2025
October 26, 2026
·
1 min read
·
Gabrielle Masson
Insights
Australia’s clinical trial advantage gains ground amid U.S. uncertainty
October 26, 2026
·
4 min read
·
Jennifer C. Smith-Parker
Policy
Roche flags ‘final opportunity’ for Germany to reestablish as a reliable investment location
October 23, 2026
·
2 min read
·
Nick Paul Taylor
